CAMBRIDGE, Mass., - October 11, 2004 - Therion Biologics Corporation today announced that Mark Leuchtenberger, President and CEO of Therion, will present a company overview and corporate update at the Biotechnology Industry Organization (BIO) Emerging Company Investor Forum. The Therion presentation will take place on Wednesday, October 13th 2004, at 11:30 a.m. PT.

During the presentation, Mr. Leuchtenberger will discuss Therion�s cancer vaccine programs which were featured in the September/October 2004 issue of FDA Consumer in an article entitled, Cancer Vaccines: Training the Immune System to Fight Cancer. The full text of the article can be viewed with the following link: http://www.fda.gov/fdac/features/2004/504_cancer.html

About Therion Biologics Corporation
Therion Biologics Corporation develops therapeutic vaccines that aim to extend and improve the lives of cancer patients. The company has two lead product candidates: PANVAC-VF, currently in a Phase III clinical trial for pancreatic cancer; and PROSTVAC�-VF currently in a Phase II clinical trial for prostate cancer. The company is applying its technology to develop its vaccine pipeline, including treatments for breast cancer, lung cancer, and the prevention of AIDS. Therion is also developing a vaccine for colon cancer with its strategic partner, Aventis Pasteur, Ltd. Through Therion�s longstanding partnerships with the National Cancer Institute (NCI) and a network of renowned clinical institutions, over 700 patients in more than 30 clinical trials have been treated with Therion�s vaccine candidates. For more information, please visit www.therionbio.com.